紫金矿业表示，分拆所涉资产全部为境外黄金矿山资产，在黄金定价逻辑发生重大变化以及价格大幅上涨的背景下，本次分拆上市预计将为公司与股东创造 更大价值。 4月30日，紫金矿业（601899）（SH601899，股价17.46元，市值4640亿元）公告称，其拟将下属境外黄金矿山资产重组至全资子公司紫金黄金国际有限公 司（以下简称"紫金黄金国际"）旗下，并申请将紫金黄金国际分拆至香港联交所主板上市。 紫金矿业的黄金资源量及产量位居全球前六，近五年矿产金产量年复合增长率达12%。 在南美洲，紫金矿业拥有哥伦比亚武里蒂卡金矿、苏里南罗斯贝尔金矿、圭亚那奥罗拉金矿及新并购的秘鲁阿瑞那铜金矿。 分拆可提升公司市值管理水平 紫金矿业称，本次拟重组整合至紫金黄金国际旗下的公司下属境外黄金矿山资产由多座世界级大型矿山组成，主要包括位于南美洲、中亚地区、非洲和大洋 洲的黄金矿山。 "相关重组工作目前尚在推进过程中。"紫金矿业表示。 本次分拆上市完成后，紫金矿业与紫金黄金国际将在资产、财务、机构、人员、业务等方面按法律法规要求致力保持独立。 紫金矿业称，目前公司董事会同意授权启动本次分拆上市的前期筹备工作，并在本次分拆上市方案制定完成 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 （九）发售原则：香港公开发售部分将根据接获认购者的有效申请数目决定配发给认购者的股份数目。 配发基准可能根据认购者在香港公开发售部分有效申请的股份数目而有所不同，但应严格按照《香港联 合交易所有限公司证券上市规则》指定（或获豁免）的比例分摊。在适当的情况下，配发股份亦可通过 抽签方式进行，即部分认购者可能获配发比其他申请认购相同股份数目的认购者较多的股份，而未获抽 中的认购者可能不会获配发任何股份。公开发售部分与国际配售的部分的比例将按照《香港联合交易所 有限公司证券上市规则》规定的超额认购倍数以及香港联交所可能授予的有关豁免而设定"回拨"机制。 国际配售部分占本次发行的比例将根据香港公开发售部分比例（经回拨后）来决定。国际配售部分的配 售对象和配售额度将根据累计订单，充分考虑各种因素决定，包括但不限于：总体超额认购倍数、投资 者的质量、投资者的重要性和在过去交易中的表现、投资者下单的时间、订单的大小、价格的敏感度、 预路演的参与程度、对该投资者后市行为的预计等。在本次国际配售分配中，将依照与基石投资者签署 的相关协议优先考虑基石投资者（如有）。 在不允许就安 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000333 证券简称：美的集团 公告编号：2025-028 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、法定代表人、主管会计工作负责人及会计机构负责人声明：保证季度报告中财务信息的真实、准 确、完整。 3、第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 ■ 追溯调整或重述原因 财政部于2024年12月发布了《企业会计准则解释第18号》（以下简称"解释18号"），公司执行了解释18 号中关于不属于单项履约义务的保证类质量保证的会计处理规定，将可比期间的相关保证类产品质保费 自销售费用重分类至营业成本，影响金额列示如下： ■ 公司新能源及工业技术、智能建筑科技、机器人与自动化报告期收入分别为111亿元同比增长45%，99 亿元同比增长2 ...

紫金矿业（601899）公告，为加快黄金板块国际化进程，公司拟将下属境外黄金矿山资产重组至紫金黄 金国际，并申请分拆至香港联交所主板上市。本次分拆上市有利于黄金资产价值重估和公司整体利益， 不会影响紫金矿业对境外黄金资产的控制权。紫金黄金国际仍为紫金矿业合并报表范围内的控股子公 司。分拆所涉资产全部为境外黄金矿山资产，主要包括位于南美、中亚、非洲和大洋洲的黄金矿山。本 次分拆上市尚处于前期筹划阶段，需取得有关部门的相关审批许可后方可实施。 ...

消息人士指出，最快今年内可能完成分拆计划，索尼拟将大部分半导体业务股份分配给现有股 东，并在分拆后保留少数股权。由于市场因美国总统特朗普关税政策波动剧烈，分拆计划仍在 审议中，细节可能有所变动。 国芯网[原:中国半导体论坛] 振兴国产半导体产业！ 不拘中国、 放眼世界 ！ 关注 世界半导体论坛 ↓ ↓ ↓ 知情人士称，索尼正考虑剥离旗下半导体业务 Sony Semiconductor Solutions Corp. 分拆 并将其上市，借此简化公司结构、聚焦娱乐领域。 加群步骤: 第一步： 扫描下方二维码，关注国芯网微信公众号。 索尼的一位发言人回应称："这篇报道是基于猜测，并没有这样的具体计划。" 这家日本科技巨头还计划分拆其金融业务，此举与亿万富翁投资者Dan Loeb多年前提出的价 值释放方案不谋而合。多年前，索尼曾拒绝洛布旗下Third Point基金提出的改革要求，该基 金已于2020年清仓索尼ADR。 索尼芯片业务为苹果(AAPL.US)等手机厂商提供全球领先的图像传感器。独立运营将赋予该业 务更大决策灵活性，便于快速应对市场变化并拓宽融资渠道。上个财年，该部门贡献了约1.7 万亿日元(120亿美元 ...

美的集团：拟分拆安得智联至香港联交所主板上市 智通财经4月29日电，美的集团(000333.SZ)公告称，公司拟分拆所属子公司安得智联供应链科技股份有 限公司至香港联交所主板上市。本次分拆完成后，美的集团股权结构不会发生重大变化，且仍将维持对 安得智联的控制权。本次分拆有利于公司进一步理顺业务管理架构，释放智慧物流板块估值潜力；有利 于安得智联拓宽融资渠道，完善激励机制，提升企业竞争力。 ...

标普全球计划将其移动部门分拆为一家独立的上市公司。 ...

Core Viewpoint - Kangzheng Pharmaceutical is planning to spin off its subsidiary, Demai Pharmaceutical, which focuses on skin health, for independent listing on the Hong Kong Stock Exchange. This move raises questions about whether it is a strategic decision or an attempt to offload a loss-making entity [1][4]. Group 1: Spin-off Details - The spin-off will involve a distribution of 90.8% of Demai's shares to existing shareholders, with no new stock issuance for financing. This allows shareholders to directly hold shares of Demai and benefit from independent valuation premiums [1][2]. - Demai Pharmaceutical has shown revenue growth from 384 million yuan in 2022 to 618 million yuan in 2024, but its losses have also increased from 55.17 million yuan to 106 million yuan during the same period [2][3]. Group 2: Financial Performance - Demai's gross margin for prescription drugs is projected to decline from 76.6% in 2023 to 61.7% in 2024, contributing to an overall gross margin drop from 76.9% to 63.5% [2][3]. - The company's sales expense ratio has risen from 57.7% to 62.9%, with sales expenses reaching 388 million yuan in 2024, nearly matching its gross profit [2][3]. Group 3: Strategic Context - Kangzheng Pharmaceutical is facing significant performance pressure, with a revenue decline of 6.8% to 7.469 billion yuan and a net profit drop of 32.3% to 1.613 billion yuan in 2024. The decline is attributed to the impact of national procurement policies on key products [4][5]. - The spin-off aims to achieve three objectives: shedding the loss-making skin business, allowing Demai to raise capital independently, and enhancing the overall market valuation of the group by focusing on higher-margin areas [4][5]. Group 4: Market Landscape - The skin health market is projected to grow significantly, with an estimated market size of 254.9 billion yuan by 2035 and a compound annual growth rate exceeding 15% [4]. - However, Demai faces intense competition from stronger players in the skin health sector, and its reliance on generic products and high sales expenses raises concerns about sustainability [5].

Core Viewpoint - 康哲药业's subsidiary 德镁医药 is planning to spin off and independently list on the Hong Kong Stock Exchange, despite facing losses in recent years [1][2] Group 1: Company Overview - 德镁医药 is primarily responsible for 康哲药业's skin health business in China, focusing on innovative pharmaceutical solutions for skin conditions [1] - The company has developed a diverse product portfolio addressing significant unmet clinical needs in major skin disease areas, including three marketed prescription products for conditions like psoriasis [1] Group 2: Financial Performance - 德镁医药 has reported losses for the past three years, with revenues of 383 million yuan, 473 million yuan, and 618 million yuan from 2022 to 2024, while net profits were -55.17 million yuan, -4.703 million yuan, and -106 million yuan respectively [2] - The revenue growth is attributed to increased sales of prescription drugs and dermatological skincare products, while losses are mainly due to high marketing and R&D expenses related to new product launches [2] Group 3: Spin-off Purpose - The spin-off aims to allow 德镁医药 to raise capital directly from the market, providing financial support for its existing operations and future expansion [2] - After the spin-off, 康哲药业 will no longer hold any equity in 德镁医药, which will cease to be a subsidiary [2]

Group 1 - The core point of the article is that Kangzheng Pharmaceutical is planning to spin off its subsidiary, Demai Pharmaceutical, which holds 90.8% of its shares, to list on the Hong Kong Stock Exchange, aiming to enhance both companies' market positions and attract investors [1][4] - Demai Pharmaceutical, established in 2020, focuses on skin prescription drugs and dermatological skincare products, providing comprehensive solutions for skin health [2][5] - The company has a product pipeline that includes three marketed products and several candidates in various stages of development, targeting common skin diseases such as psoriasis and acne [2][3] Group 2 - Demai Pharmaceutical reported revenues of approximately 1.5 billion yuan over the past three years, with a net loss of 160 million yuan, indicating a trend of increasing revenue but persistent losses [2][3] - The revenue growth is attributed to increased sales of skin prescription drugs and dermatological skincare products, alongside high promotional and R&D expenses [5][6] - The spin-off is expected to provide Demai Pharmaceutical with greater autonomy in resource allocation and strategic decision-making, potentially leading to improved operational efficiency and market opportunities in the skin health sector [6][7]